Monod Bio licenses AI-designed protein technologies to SignalChem for drug discovery assays

The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform.

Monod Bio has granted SignalChem Biotech a non-exclusive licence to incorporate its AI-designed LuxSit luciferase technology and NovoBodies into custom luminescent assays and protein-fusion services for third-party research customers. 

The agreement provides Monod Bio with another commercial channel for its de novo protein-design platform while expanding SignalChem and parent company Sino Biological’s AI-enabled drug discovery and life-science research capabilities.

Field	Content
Alert Type	Deal
Companies	Monod Bio; SignalChem Biotech; Sino Biological
Deal Type	Non-exclusive technology licensing agreement
Asset or Company	LuxSit de novo luciferase technology and NovoBodies
Therapy Area(s)	Drug discovery; Life sciences research; Diagnostics
Technology or Modality	AI-designed proteins; De novo protein design; Luminescent biosensors; Engineered binding proteins
Deal Value	Financial terms were not disclosed. SignalChem’s parent company Sino Biological said revenue associated with the business is not expected to have a material impact on its overall financial performance. (PR Newswire)
Development Stage	Commercial research-use technology platform
Geography	United States; Canada; Global
What Happened	On 26 August 2026, Monod Bio and SignalChem Biotech, a wholly owned subsidiary of Sino Biological, announced a non-exclusive licensing agreement covering Monod Bio’s LuxSit de novo luciferase technology and NovoBodies. SignalChem can incorporate the technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. The companies did not disclose financial terms. (PR Newswire)
Why It Matters	The agreement moves Monod Bio’s AI-designed proteins beyond internal technology development by embedding them within commercial research services available to external drug discovery customers. For SignalChem, the licence adds AI-designed protein components that could support development of specialised assays and discovery tools for complex biological targets. (PR Newswire)
Supporting Context	LuxSit is an AI-designed luciferase engineered for use in luminescent biosensors, while NovoBodies are compact and highly stable binding proteins designed to recognise different biological targets. Monod Bio develops novel proteins using AI-powered de novo protein design and commercialises the technology through its “Monod Inside” partnership model. (PR Newswire)
Strategic Rationale	Monod Bio gains access to SignalChem and Sino Biological’s customer base and global life-science services infrastructure without granting exclusive rights to its technologies. SignalChem expands its CRO offering with AI-designed protein capabilities, supporting Sino Biological’s broader strategy of integrating AI-enabled technologies into its research tools and services portfolio. (PR Newswire)
Potential Impact	The partnership could increase adoption of AI-designed proteins within research assays and discovery workflows by making the technologies accessible through an established CRO provider. Its commercial significance will depend on customer adoption, and Sino Biological has cautioned that the business is not currently expected to have a material impact on its overall financial performance. (PR Newswire)
Key Takeaway	Monod Bio is using a licensing model to put its AI-designed proteins directly into SignalChem’s commercial discovery services, extending its platform into third-party drug research workflows.
What to Watch	Adoption of LuxSit and NovoBodies by SignalChem customers, expansion into additional assay and protein-fusion applications and whether Monod Bio signs further “Monod Inside” licensing partnerships with life-science tools and services companies.
Primary Source	Monod Bio / SignalChem Biotech licensing announcement
Relevant Date	26 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com